Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The role of PRMT5/WDR77 complex in promoting breast cancer oncogenesis [RNA-Seq_HPTB]

ABSTRACT: Comprehensive RNA-seq experiments in DMSO and HPTB (inhibitor of PRMT5) treated cells delineate the role of PRMT5 complex in promoting breast cancer oncogenesis

ORGANISM(S): Homo sapiens

PROVIDER: GSE75742 | GEO | 2017/12/31

SECONDARY ACCESSION(S): PRJNA305260

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The role of PRMT5/WDR77 complex in promoting breast cancer oncogenesis [RNA-Seq]

Project description:Comprehensive RNA-seq experiments in control and PRMT5 and WDR77 shRNA infected cells delineate the role of PRMT5/WDR77 complex in promoting breast cancer oncogenesis

2017-12-31 | GSE75741 | GEO

The role of PRMT5/WDR77 complex in promoting breast cancer oncogenesis

Project description:The role of PRMT5/WDR77 complex in promoting breast cancer oncogenesis

| PRJNA305256 | ENA

The role of PRMT5/WDR77 complex in promoting breast cancer oncogenesis [ChIP-Seq]

Project description:The PRMT5/WDR77 complex is known to regulate alternative splicing through the symmetric dimethylation of spliceosome proteins in the cytoplasm. Overexpression of this complex is observed in different types of cancer including breast cancer, where it shows increased nuclear accumulation.To understand the nuclear role and the chromatin binding properties of PRMT5 we performed genome-wide ChIP-Seq analysis in the breast cancer cell line MDA-MB-231.

2017-12-31 | GSE75739 | GEO

The role of PRMT5/WDR77 complex in promoting breast cancer oncogenesis

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-12-31 | GSE75743 | GEO

Genome-wide analysis of genes regulated by p44/wdr77 and PRMT5 in lung and prostate cancer cells

Project description:Analysis of gene expression in lung and prostate cancer cells expressing non-target (NT), p44/wdr77. or PRMT5 shRNA. Results provide important information on how p44/wdr77 and PRMT5 control cellular proliferation. Total RNA obtained from cells expressing NT, p44/wdr77, or PRMT5 shRNA.

2014-04-14 | E-GEOD-56757 | biostudies-arrayexpress

Transcriptomic Analysis Reveals Co-Regulation by PRMT5 and WDR77 in HSC-5 Cells

Project description:CRISPR was utilized to deplete either PRMT5 or WDR77 in HSC-5 cells. Subsequently, RNA-seq was performed to identify changes in the transcriptome following the loss of PRMT5 or WDR77 in these cells. Critically, Gene Set Enrichment Analysis (GSEA) was conducted to screen and identify a list of genes co-regulated by PRMT5 and WDR77.

2024-09-19 | GSE272319 | GEO

The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer.

Project description:We observed overexpression and increased intra-nuclear accumulation of the PRMT5/WDR77 in breast cancer cell lines relative to immortalized breast epithelial cells. Utilizing mass spectrometry and biochemistry approaches we identified the Zn-finger protein ZNF326, as a novel interaction partner and substrate of the nuclear PRMT5/WDR77 complex. ZNF326 is symmetrically dimethylated at arginine 175 (R175) and this modification is lost in a PRMT5 and WDR77-dependent manner. Loss of PRMT5 or WDR77 in MDA-MB-231 cells leads to defects in alternative splicing, including inclusion of A-T rich exons in target genes, a phenomenon that has previously been observed upon loss of ZNF326. We observed that the alternatively spliced transcripts of a subset of these genes, involved in proliferation and tumor cell migration like REPIN1/AP4, ST3GAL6, TRNAU1AP and PFKM are degraded upon loss of PRMT5. In summary, we have identified a novel mechanism through which the PRMT5/WDR77 complex maintains the balance between splicing and mRNA stability through methylation of ZNF326.

| S-EPMC5737218 | biostudies-literature

Genome-wide analysis of genes regulated by p44/wdr77 and PRMT5 in lung and prostate cancer cells

2014-04-14 | GSE56757 | GEO

Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Project description:PRMT5 Co-IP mass spectrometry: Lysates of MCF-7 RB1-knockout cells were pulled down with a PRMT5 antibody or IgG control. The pulldowns were subjected to mass spectrometry analysis. QEX2_981005, QEX2_981006, QEX2_981007: DMSO, IgG QEX2_981008, QEX2_981009, QEX2_981010: DMSO, PRMT5 antibody QEX2_981011, QEX2_981012, QEX2_981013, GSK, IgG QEX2_981014, QEX2_981015, QEX2_981016, GSK, PRMT5 antibody SDMA PTM analysis: MCF-7 RB1-knockout cells were transfected with a PRMT5 siRNA or a control siRNA. Lysates were collected three days after transfection and subjected to mass spectrometry analysis. LUM1_1000791, LUM1_1000792, LUM1_1000793: control SiRNA LUM1_1000794, LUM1_1000795, LUM1_1000796: PRMT5 siRNA [

2024-01-12 | PXD046996 | Pride

Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

2023-06-30 | MSV000092321 | MassIVE